FMOD expression in whole blood aids in distinguishing between chronic lymphocytic leukemia and other leukemic lymphoproliferative disorders. A pilot study.
Marc SorigueJordi JuncaChristelle FerraSilvia MarceNeus Ruiz-XivilléLaia PinyolMarta CabezonAndrea EspasaDiana DominguezLaia Lopez-ViaplanaRocio RuizJoan BuchEsther PlensaSilvia-Zdenka MostacedoJessica ArandaSara VergaraMinerva RayaIsabel GranadaGustavo TapiaJose-Tomas NavarroSilvia BeàLurdes ZamoraPublished in: Cytometry. Part B, Clinical cytometry (2020)
This study could suggest that borderline LPDs may constitute a distinct group laying in the biological spectrum of chronic leukemic LPDs. Future studies will have to confirm these results with other biological data. Quantification of FMOD can potentially be of help in the diagnosis of phenotypically complex LPDs.